BACKGROUND: There is conflicting evidence on the role of acetylsalicylic acid (ASA) use in the development of cardiac allograft vasculopathy (CAV). METHODS: A nationwide prospective two-center study investigated changes in the coronary artery vasculature by highly automated 3-D optical coherence tomography (OCT) analysis at 1 month and 12 months after heart transplant (HTx). The influence of ASA use on coronary artery microvascular changes was analyzed in the overall study cohort and after propensity score matching for selected clinical CAV risk factors. RESULTS: In total, 175 patients (mean age 52 ± 12 years, 79% male) were recruited. During the 1-year follow-up, both intimal and media thickness progressed, with ASA having no effect on its progression. However, detailed OCT analysis revealed that ASA use was associated with a lower increase in lipid plaque (LP) burden (p = .013), while it did not affect the other observed pathologies. Propensity score matching of 120 patients (60 patient pairs) showed similar results, with ASA use associated with lower progression of LPs (p = .002), while having no impact on layered fibrotic plaque (p = .224), calcification (p = .231), macrophage infiltration (p = .197), or the absolute coronary artery risk score (p = .277). According to Kaplan-Meier analysis, ASA use was not associated with a significant difference in survival (p = .699) CONCLUSION: This study showed a benefit of early ASA use after HTx on LP progression. However, ASA use did not have any impact on the progression of other OCT-observed pathologies or long-term survival.

2nd Department of Internal Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Prague Czech Republic

Cardiovascular and Transplantation Surgery Brno Czech Republic

Department of Cardiology IKEM Prague Czech Republic

Department of Cardiovascular Diseases St Anne's University Hospital and Masaryk University Brno Brno Czech Republic

Department of Preventive Cardiology IKEM Prague Czech Republic

Iowa Institute for Biomedical Imaging The University of Iowa Iowa City Iowa USA

Zobrazit více v PubMed

Khush KK, Cherikh WS, Chambers DC, et al. The international thoracic organ transplant registry of the International society for heart and lung transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38:1056–66. doi: 10.1016/j.healun.2019.08.004 PubMed DOI PMC

Hsich E, Singh TP, Cherikh WS, et al. The International thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-ninth adult heart transplantation report-2022; focus on transplant for restrictive heart disease. J Heart Lung Transplant 2022; 41:1366–75. doi: 10.1016/j.healun.2022.07.018 PubMed DOI PMC

Chih S, Chong AY, Mielniczuk LM, et al. Allograft vasculopathy: the achilles’ heel of heart transplantation. J Am Coll Cardiol 2016; 68:80–91. doi: 10.1016/j.jacc.2016.04.033 PubMed DOI

Matsuo Y, Cassar A, Li J, et al. Repeated episodes of thrombosis as a potential mechanism of plaque progression in cardiac allograft vasculopathy. Eur Heart J 2013; 34:2905–15. doi:10.1093/eurheartj/eht209 PubMed DOI PMC

Kim M, Bergmark BA, Zelniker TA, et al. Early aspirin use and the development of cardiac allograft vasculopathy. J Heart Lung Transplant 2017; 36:1344–49. doi: 10.1016/j.healun.2017.06.015 PubMed DOI

Peled Y, Lavee J, Raichlin E, et al. Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up. Clin Transplant 2017;31: e13133. doi:10.1111/ctr.13133 PubMed DOI

Costanzo MR, Dipchand A, Starling R, et al. The International society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29:914–56. doi: 10.1016/j.healun.2010.05.034 PubMed DOI

Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023;42(5):e1–e141. doi:10.1016/j.healun.2022.10.015 PubMed DOI

Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24:1710–20. doi: 10.1016/j.healun.2005.03.019 PubMed DOI

Berry GJ, Burke MM, Andersen C, et al. The 2013 International society for heart and lung transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013; 32:1147–62. doi: 10.1016/j.healun.2013.08.011 PubMed DOI

Pazdernik M, Chen Z, Bedanova H, et al. Early detection of cardiac allograft vasculopathy using highly automated 3-dimensional optical coherence tomography analysis. J Heart Lung Transplant 2018; 37:992–1000. doi: 10.1016/j.healun.2018.04.002 PubMed DOI

Chen Z, Pazdernik M, Zhang H, et al. Quantitative 3D Analysis of Coronary Wall Morphology in Heart Transplant Patients: OCT-Assessed Cardiac Allograft Vasculopathy Progression. Med Image Anal. 2018;50:95–105. doi:10.1016/j.media.2018.09.043 PubMed DOI PMC

Jensen NM, Chen Z, Clemmensen TS, et al. Validation of a semi-automatic software for optical coherence tomography - analysis in heart transplanted patients. Int J Cardiovasc Imaging 2023; 39:257–68. doi:10.1007/s10554-022-02722-9 PubMed DOI PMC

Pazdernik M, Bedanova H, Chen Z, et al. Donor specific anti-HLA antibodies and cardiac allograft vasculopathy: A prospective study using highly automated 3-D optical coherence tomography analysis. Transpl Immunol 2021; 65:101340. doi: 10.1016/j.trim.2020.101340 PubMed DOI PMC

Potena L, Holweg CTJ, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation. 2006; 82:398–405. doi:10.1097/01.tp.0000229039.87735.76 PubMed DOI

Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96:1398–402. doi: 10.1161/01.cir.96.5.1398 PubMed DOI

Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Eng J Med 1995; 333:621–7. doi:10.1056/NEJM199509073331003 PubMed DOI

Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Eng J Med 2003; 349:847–58. doi:10.1056/NEJMoa022171 PubMed DOI

Clemmensen TS, Holm NR, Eiskjær H, et al. Detection of early changes in the coronary artery microstructure after heart transplantation: A prospective optical coherence tomography study. J Heart Lung Transplant 2018; 37:486–95. doi: 10.1016/j.healun.2017.10.014 PubMed DOI

Cassar A, Matsuo Y, Herrmann J, et al. Coronary atherosclerosis with vulnerable plaque and complicated lesions in transplant recipients: new insight into cardiac allograft vasculopathy by optical coherence tomography. Eur Heart J. 2013; 34:2610–17. doi:10.1093/eurheartj/eht236 PubMed DOI PMC

Oberkofler CE, Raptis DA, Müller PC, et al. Low-dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation. Liver Transpl. 2022. Dec;28(12):1888–1898. doi: 10.1002/lt.26534. Epub 2022 Aug 5. PubMed DOI PMC

Zhang X, Chang A, Zou Y, et al. Aspirin Attenuates Cardiac Allograft Rejection by Inhibiting the Maturation of Dendritic Cells via the NF-κB Signaling Pathway. Front Pharmacol. 2021. Aug 16;12:706748. doi: 10.3389/fphar.2021.706748. PubMed DOI PMC

McManus BM, Horley KJ, Wilson JE, et al. Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy. Am J Pathol. 1995; 147:293–308. PubMed PMC

Bjerre KP, Clemmensen TS, Berg K, et al. Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy. J Heart Lung Transplant 2020; 39:371–8. doi: 10.1016/j.healun.2020.01.1344 PubMed DOI

Asleh R, Briasoulis A, Smith B, et al. Association of aspirin treatment with cardiac allograft vasculopathy progression and adverse outcomes after heart transplantation. J Card Fail 2021; 27:542–51. doi: 10.1016/j.cardfail.2021.01.019 PubMed DOI

Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006; 99:801–15. doi: 10.1161/01.RES.0000246086.93555.f3 PubMed DOI

Clemmensen TS, Holm NR, Eiskjær H, et al. Layered fibrotic plaques are the predominant component in cardiac allograft vasculopathy: systematic findings and risk stratification by OCT. JACC Cardiovasc Imaging 2017;10:773–84. doi: 10.1016/j.jcmg.2016.10.021 PubMed DOI

Cyrus T, Sung S, Zhao L,et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2002; 106:1282–7. doi: 10.1161/01.cir.0000027816.54430.96 PubMed DOI

Nishimura S, Ehara S, Hasegawa T, et al. Cholesterol crystal as a new feature of coronary vulnerable plaques: An optical coherence tomography study. J Cardiol 2017; 69:253–9. doi: 10.1016/j.jjcc.2016.04.003 PubMed DOI

Fry L, Lee A, Khan S, et al. Effect of aspirin on cholesterol crystallization: A potential mechanism for plaque stabilization. Am Heart J Plus Cardiol Res Pract 2022; 13:100083. doi: 10.1016/j.ahjo.2021.100083 PubMed DOI PMC

Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature 2010; 464:1357–61. doi:10.1038/nature08938 PubMed DOI PMC

Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events-a novel insight into plaque rupture by scanning electron microscopy. Scanning 2006; 28:1–10. doi:10.1002/sca.4950280101 PubMed DOI